These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10435505)

  • 1. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
    Ondo W; Hunter C; Almaguer M; Jankovic J
    Mov Disord; 1999 Jul; 14(4):664-8. PubMed ID: 10435505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease.
    Ondo W; Hunter C; Almaguer M; Gancher S; Jankovic J
    Clin Neuropharmacol; 1999; 22(1):1-4. PubMed ID: 10047926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
    Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
    J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
    Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
    Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
    [No Abstract]   [Full Text] [Related]  

  • 9. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
    Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
    Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy.
    Bhidayasiri R; Phokaewvarangkul O; Boonpang K; Boonmongkol T; Thongchuem Y; Kantachadvanich N; García Ruiz PJ
    Clin Neuropharmacol; 2019; 42(5):172-178. PubMed ID: 31567642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.
    Trosch RM; Silver D; Bottini PB
    CNS Drugs; 2008; 22(6):519-27. PubMed ID: 18484793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
    Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
    J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
    Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):385-393. PubMed ID: 38578533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.